Chinanews.com Beijing, February 26. The "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" announced by the National Medical Security Administration and the Ministry of Human Resources and Social Security on December 28, 2020 will be It will be officially implemented on March 1, 2021.
Among them, Pfizer, the world's first fusion protein tumor necrosis factor inhibitor Enli (etanercept) approved for the treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), was successfully included in the National Medical Insurance List. Become a biological agent in the catalog with both price advantage and clinical value advantage.
Statistics show that there are nearly 10 million patients with rheumatoid arthritis and ankylosing spondylitis in China.
Among them, the peak incidence of rheumatoid arthritis is between 30 and 50 years old. Most of the patients with ankylosing spondylitis are young men, and they are in the middle and young ages, the most important labor force and family pillar in society.
However, rheumatoid arthritis and ankylosing spondylitis have low intensive treatment rates, low patient compliance rates, and high disability rates in China. Long-term treatment has brought a heavy burden to patients, their families and society.
Professor Zhao Yan of the Rheumatology Branch of the Chinese Medical Association and Professor of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital said that early standardized treatment and "treatment standards" can improve the prognosis of patients with rheumatoid arthritis and ankylosing spondylitis and reduce the disability rate. It is extremely important to reduce the burden on patients and society.
"In fact, rheumatoid arthritis and ankylosing spondylitis can be fully controlled through timely and effective treatment. If the control is well and the standards are met, the patient can return to normal movement and work ability. Clinicians should try their best In a short period of time, patients can achieve clinical remission, and achieving anti-inflammatory standards is the focus and key to the treatment of rheumatoid arthritis and ankylosing spondylitis."
These two types of diseases require long-term standardized treatment, and the treatment costs bring a huge economic burden to patients and society.
With the implementation of the new version of the National Medical Insurance Drug List on March 1, Enli (etanercept) is expected to become a biological agent in the catalog with both price advantages and clinical value advantages, which will further improve rheumatoid arthritis and ankylosing spondylitis Patient accessibility and affordability of innovative biologics.
Zhao Yan said: "The standardized treatment of patients with rheumatoid arthritis and ankylosing spondylitis in my country is not optimistic, and there is an urgent need to improve the availability of treatment drugs."
When ensuring the timely implementation of the national medical insurance catalogue, all provinces and cities actively explore various channels and measures such as special drug management, single-line payment, and dual-channel drug purchase to further reduce the patient's self-payment ratio, improve the convenience of patient medication, and truly benefit the people Benefit people.
In February this year, the Beijing Municipal Medical Security Bureau and the Beijing Municipal Human Resources and Social Security Bureau issued the "Notice on Adjusting and Regulating the City’s Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Reimbursement Scope Relevant Issues." Included in the scope of payment for outpatient clinics in Beijing at a fixed rate
Participants in Beijing’s basic medical insurance use etanercept for outpatients. The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%.
In addition, the Sichuan Provincial Medical Security Bureau and the Sichuan Provincial Department of Human Resources and Social Security also issued the "Notice on the Implementation of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" on February 5th. "Include 29 new drugs including etanercept in the 2020 negotiations into the list of single-line payment drugs, realizing "dual channel", that is, patients can purchase drugs in medical institutions and enjoy medical insurance reimbursement, and purchase drugs in designated pharmacies by the Medical Insurance Bureau. Can enjoy the same medical insurance reimbursement treatment.
A series of measures such as special drug management, single-line payment and dual-channel drug purchase can enable medical insurance policies to benefit patients in a better and more timely manner, and greatly enhance patients' sense of the implementation of medical insurance drug negotiations.